2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2555

Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 10L

Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial

ACR Late-Breaking Poster Session

9:00AM-11:00AM: Abstract Number: 2968

Efficacy of Anti-TNF Alpha in Severe and Refractory Cardiovascular Involvement of Behcet’s Disease: A Multicenter Observational Study of 18 Patients

Vasculitis - Poster III: Rarer Vasculitides

9:00AM-11:00AM: Abstract Number: 2894

Efficacy of Rituximab in Systemic Sclerosis with Interstitial Lung Disease

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

9:00AM-11:00AM: Abstract Number: 2672

Elderly Patients Risk a False Positive Diagnosis of Primary Sjogren’s Syndrome If a Positive Labial Gland Biopsy Is Solely Based on Focus Score

Sjögren's Syndrome - Poster II: Clinical Science

9:00AM-11:00AM: Abstract Number: 2725

Elevated Disease Activity in Disease-Related Spondyloarthritis Despite Use of Tumor Necrosis Factor Inhibitor Therapies

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2706

Elevated Levels of Serum Myeloid Related Protein 8/14 in Ankylosing Spondylitis: Associated with Peripheral Arthritis and Active Disease

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

9:00AM-11:00AM: Abstract Number: 2577

Elevated Matrix Metalloproteinases Levels in Oral Fluids of Most Rheumatoid Arthritis Patients, Even without Frank Periodontitis

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster III

9:00AM-11:00AM: Abstract Number: 2931

Endogenous Nur77 Is a Specific Indicator of Antigen Receptor Signaling in Human T and B Cells

T Cell Biology and Targets in Autoimmune Disease - Poster Session II

9:00AM-11:00AM: Abstract Number: 2459

Epidemiologic Profile of Erectile Dysfunction in SLE: A Multi-Center Study in Latin American Patients

Reproductive Issues in Rheumatic Disorders - Poster

9:00AM-11:00AM: Abstract Number: 2665

Epratuzumab Treatment of Patients with Systemic Lupus Erythematosus and Secondary Sjogren’s Syndrome: An Exploratory Analysis of Phase 3 Studies

Sjögren's Syndrome - Poster II: Clinical Science

9:00AM-11:00AM: Abstract Number: 2458

Erectile Dysfunction in Men with Rheumatic Diseases: A Systematic Review

Reproductive Issues in Rheumatic Disorders - Poster

9:00AM-11:00AM: Abstract Number: 2675

Essdai, Clinessdai and DAS Scoring at Diagnosis of Primary Sjogren Syndrome: Association with the Development of Hematologic and Solid Neoplasias in 1301 Patients

Sjögren's Syndrome - Poster II: Clinical Science

9:00AM-11:00AM: Abstract Number: 2392

Establishing Quality of Life Content Domains in Pediatric Localized Scleroderma

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

9:00AM-11:00AM: Abstract Number: 2252

Estimated Cost of SLE Hospitalizations

Health Services Research - Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].